Pierre Sujobert Selected Research

Tyrosine Kinase Inhibitors

9/2019	Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
9/2015	Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pierre Sujobert Research Topics

Disease

14	Neoplasms (Cancer) 01/2022 - 02/2013
14	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 08/2005
9	Lymphoma (Lymphomas) 01/2022 - 02/2013
4	VEXAS syndrome 01/2022 - 10/2021
4	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2018 - 05/2013
3	Leukemia 12/2021 - 12/2017
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 01/2016
2	Acute Promyelocytic Leukemia 01/2022 - 01/2017
2	B-Cell Lymphoma (Lymphoma, B Cell) 08/2021 - 01/2016
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2021 - 08/2013
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 02/2021
1	Hematologic Neoplasms (Hematological Malignancy) 02/2021
1	Residual Neoplasm 01/2021
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2020
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 09/2019
1	T-Cell Lymphoma (Lymphoma, T Cell) 11/2018
1	Sarcoma (Soft Tissue Sarcoma) 02/2018
1	Suppuration 02/2018
1	Infections 02/2018
1	Disease Progression 01/2018
1	Metabolic Diseases (Metabolic Disease) 01/2018
1	Lymphocytosis 01/2017
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2016
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2016
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 08/2013
1	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 05/2013
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 02/2013
1	Mesenteric Ischemia 08/2007

Drug/Important Bio-Agent (IBA)

4	Chimeric Antigen ReceptorsIBA 01/2022 - 11/2020
4	Mechanistic Target of Rapamycin Complex 1IBA 07/2016 - 01/2008
3	Biological ProductsIBA 01/2022 - 01/2021
3	GSK621IBA 01/2022 - 06/2015
3	Phosphotransferases (Kinase)IBA 04/2020 - 08/2013
2	RNA (Ribonucleic Acid)IBA 01/2022 - 02/2021
2	Messenger RNA (mRNA)IBA 01/2022 - 08/2013
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021 - 08/2013
2	tisagenlecleucelIBA 01/2021 - 11/2020
2	axicabtagene ciloleucelIBA 01/2021 - 11/2020
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 08/2007
2	Proteins (Proteins, Gene)FDA Link 04/2020 - 08/2013
2	Tyrosine Kinase InhibitorsIBA 09/2019 - 09/2015
2	Pharmaceutical PreparationsIBA 02/2018 - 01/2016
2	Rituximab (Mabthera)FDA Link 01/2018 - 06/2017
2	AMP-Activated Protein KinasesIBA 01/2018 - 07/2016
2	Protein Isoforms (Isoforms)IBA 01/2016 - 08/2005
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2016 - 01/2008
1	Chlorambucil (Leukeran)FDA Link 01/2022
1	ruxolitinibIBA 01/2022
1	Janus Kinase InhibitorsIBA 01/2022
1	Codon (Codons)IBA 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2022
1	EnzymesIBA 01/2022
1	AA amyloidosisIBA 12/2021
1	CPX-351IBA 12/2021
1	Lenalidomide (CC 5013)FDA Link 10/2021
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 08/2021
1	Circulating Tumor DNAIBA 06/2021
1	Biological FactorsIBA 01/2021
1	Calcitriol Receptors (Calcitriol Receptor)IBA 01/2020
1	Antimitotic AgentsIBA 01/2020
1	Vitamin D FDA LinkGeneric 01/2020
1	blinatumomabIBA 10/2019
1	Azacitidine (5 Azacytidine)FDA Link 11/2018
1	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 02/2018
1	NucleotidesIBA 01/2018
1	ParaffinIBA 01/2018
1	Formaldehyde (Formol)FDA Link 01/2018
1	Co-Repressor ProteinsIBA 10/2017
1	Peroxidase (Myeloperoxidase)IBA 01/2017
1	ibrutinibIBA 01/2017
1	idelalisibIBA 01/2016
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2016
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2016
1	Glutamine (L-Glutamine)FDA Link 09/2015
1	fms-Like Tyrosine Kinase 3IBA 09/2015
1	proto-oncogene proteins pimIBA 09/2015
1	Tyrosine (L-Tyrosine)FDA Link 08/2013
1	AntibodiesIBA 05/2013
1	StathminIBA 05/2013
1	CyclinsIBA 02/2013
1	Cyclin D1IBA 02/2013
1	TOR Serine-Threonine KinasesIBA 01/2008
1	Insulin (Novolin)FDA Link 01/2008
1	C-Reactive ProteinIBA 08/2007
1	SteroidsIBA 08/2007
1	Phosphatidylinositols (Phosphatidylinositol)IBA 08/2005

Therapy/Procedure

8	Therapeutics 01/2022 - 08/2007
4	Drug Therapy (Chemotherapy) 01/2021 - 04/2019
2	Hematopoietic Stem Cell Transplantation 01/2022 - 01/2021
1	Homologous Transplantation 10/2021
1	Transjugular Intrahepatic Portasystemic Shunt 06/2021
1	Stem Cell Transplantation 01/2021
1	Aftercare (After-Treatment) 01/2018
1	Induction Chemotherapy 01/2018
1	Immunotherapy 10/2017
1	Precision Medicine 10/2017